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Abstract
Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are 
increased, with some degree of overlap with other phenotypes. Systematic reviews 
assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (al-
phabetical order) vs standard of care for patients with uncontrolled severe allergic 
asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and 
health economic evaluations, published in English. Critical and important asthma-
related outcomes were evaluated. The risk of bias and the certainty of the evidence 
were assessed using GRADE. All three biologicals reduced with high certainty the 
annualized asthma exacerbation rate: benralizumab incidence rate ratios (IRR) 0.63 
(95% CI 0.50 − 0.81); dupilumab IRR 0.58 (95%CI 0.47 − 0.73); and omalizumab IRR 
0.56 (95%CI 0.42 − 0.73). Benralizumab and dupilumab improved asthma control with 
high certainty and omalizumab with moderate certainty; however, none reached the 
minimal important difference (MID). Both benralizumab and omalizumab improved 
QoL with high certainty, but only omalizumab reached the MID. Omalizumab enabled 
ICS dose reduction with high certainty. Benralizumab and omalizumab showed an in-
crease in drug-related adverse events (AEs) with low to moderate certainty. All three 
biologicals had moderate certainty for an ICER/QALY value above the willingness to 
pay threshold. There was high certainty that in children 6-12 years old omalizumab 
decreased the annualized exacerbation rate [IRR 0.57 (95%CI 0.45-0.72)], improved 
QoL [relative risk 1.43 (95%CI 1.12 −1.83)], reduced ICS [mean difference (MD) −0.45 
(95% CI −0.58 to −0.32)] and rescue medication use [ MD −0.41 (95%CI −0.66 to 
−0.15)].
K E Y W O R D S
benralizumab, dupilumab, exacerbations, omalizumabsevere allergic asthma
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1  | BACKGROUND
Allergic asthma is a frequent asthma phenotype. It is usually defined 
by the presence of sensitization to environmental allergens, with 
a clinical correlation between exposure and symptoms supporting 
the diagnosis.1-3 The immunopathological distinction between al-
lergic and “nonallergic” asthma or between eosinophilic and aller-
gic asthma is not so clear. Total immunoglobulin (Ig) E levels, usually 
higher compared with “nonallergic” asthma, may overlap between 
the allergic and “nonallergic” asthma. The atopic background is asso-
ciated with increased type 2 (T2) cytokines (interleukin (IL)-4, IL-13 
and IL-5) and IL-33, IL-25 and TSLP potentiate T2 inflammation.4-8 
Abrogation of IL-4Rα signalling after established allergic airway dis-
ease prevents the development of ovalbumin-induced airway hyper-
reactivity, eosinophilia and goblet cell metaplasia.9 Targeting the IgE 
pathway with omalizumab might reduce sputum and tissue eosino-
phils, CD3+, CD4 + and CD8 + T lymphocytes, B lymphocytes and 
cells staining for interleukin-4, although this was not replicated in all 
studies.10,11
Allergic asthma clinical spectrum ranges from mild to severe. 
Atopy has been reported to be inversely associated with persistent 
airflow obstruction and airway remodelling.12 The true prevalence of 
severe allergic asthma is difficult to estimate. The proportion of asth-
matics with severe disease and a negative skin prick test varies from 
17% to 34% in the Severe Asthma Research Program (SARP) study 
to 50% in the European Network for Understanding Mechanisms of 
Severe Asthma (ENFUMOSA) study.13,14 The Unbiased Biomarkers 
for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) 
cohort reported a 76.6% incidence of atopy in severe asthma, in-
cluding nonsmokers, smokers and ex-smokers.15 Allergic asthma 
was reported to be associated with greater healthcare utilization 
and costs.16
From its availability, for clinical use nearly two decades ago for 
severe asthma, omalizumab, the first biological acknowledged by 
Global Initiative on Asthma (GINA) as add-on therapy against severe 
uncontrolled asthma, has gained strong evidence of efficacy and 
safety in the treatment of severe asthma not controlled by standard-
of-care therapy. It is licensed for severe (and moderate in USA) IgE-
mediated allergic asthma.17,18 Benralizumab, a monoclonal antibody 
that binds to the α subunit of IL-5 receptor (IL-5Rα), was recently ap-
proved for severe eosinophilic asthma.19,20 Dupilumab, a monoclonal 
antibody directed against the α subunit of the IL-4 receptor (IL-4Rα) 
acting as a dual antagonist of both IL-4 and IL-13, was approved for 
severe type 2 asthma.21,22
The European Academy of Allergy and Clinical Immunology 
(EAACI) is developing clinical practice guidelines for the use of bi-
ologicals in patients with severe asthma. This systematic review 
(SR) assessed the current evidence for the efficacy, safety and the 
economic impact for benralizumab, dupilumab and omalizumab (al-




The EAACI Asthma Voting Panel and Guidelines Steering 
Committee include clinicians and researchers with different back-
grounds (the complete list of experts is available from the EAACI 
website) whom voluntarily participate in the development of 
EAACI clinical practice guidelines for the use biologicals in severe 
asthma. They are referred to as the Guideline Development Group 
(GDG).
2.2 | Structured question and outcome prioritization
The GDG framed the clinical question as “Is treatment with ben-
ralizumab, dupilumab and omalizumab efficacious and safe for 
patients with allergic asthma?” For the purpose of this system-
atic review, the population was defined as subjects diagnosed 
with moderate to severe allergic asthma with asthma symptoms 
due to exposure to a perennial aeroallergen and serum Ig E lev-
els of 30-1300 IU/mL not be adequately controlled on inhaled 
steroids (ICS) and/or other background controllers. The asthma-
related outcomes were prioritized by the GDG using a 1-9 scale 
(7-9 critical; 4-6 important; and 1-3 of limited importance), as 
suggested by the GRADE approach. The critical outcomes were 
as follows: exacerbations, asthma control measured by the 
Asthma Control Questionnaire (ACQ) and asthma control test 
(ACT), quality of life (QoL) measured by asthma quality of life 
questionnaire (AQLQ) and safety. The important outcomes were 
as follows: lung function measured by the force expiratory vol-
ume at first second (FEV1), decrease in inhaled corticosteroids 
(ICS) and oral corticosteroids (OCS) dose, and rescue medication 
use (Table S1).
The GDG also framed a cost-effectiveness question to assess 
the economic impact of these biologicals vs standard of care. The 
outcomes of interest were costs and resources use, the incremental 
cost-effectiveness ratios (ICERs) per both quality-adjusted life-years 
(QALY) and asthma-related outcomes.
2.3 | Data sources and searches
MEDLINE (via PubMed, January 2019), EMBASE (via Ovid, January 
2019) and CENTRAL (via The Cochrane Library, January 2019) da-
tabases were searched using predefined algorithms for both SR and 
individual studies for the evidence of efficacy, safety and economic 
evaluations. Search terms were adapted to each database, and vali-
dated filters were used to retrieve appropriate designs. The refer-
ences of included studies were revised as well. Members of the GDG 
were requested to provide additional studies.
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2.4 | Study selection
The SR included only randomized controlled trials (RCTs) of pa-
tients with uncontrolled severe allergic asthma that compared ben-
ralizumab, dupilumab and omalizumab as add-on to the standard of 
care vs placebo. Separate searches were performed for each of the 
three biologicals evaluated. Only studies published in English were 
included. Abstracts or conference communications not published as 
full articles in peer-reviewed journals and RCTs using doses or routes 
not approved by US Food and Drug Administration Agency (FDA) 
and/or the European Medicines Agency (EMA) were excluded. Two 
reviewers independently assessed the references based on title and 
abstract. Then, two reviewers independently assessed the eligibil-
ity of the studies according to inclusion criteria based on full text. 
Discrepancies were solved by consensus or with the help of a third 
reviewer. All citations retrieved were imported into bibliographic 
reference software (EndNote X5; Thomson Reuters) to discard du-
plicates and record screening decisions.
2.5 | Data extraction and risk of bias assessment
Details of the study design, patient population, setting, follow-up and 
results were extracted by one reviewer and confirmed by a second 
reviewer. If needed, additional data from the authors of the included 
studies were requested. The risk of bias (ROB) was assessed using 
the Cochrane Risk of Bias Assessment Tool. Each domain (random se-
quence generation, allocation concealment, blinding of participants and 
personnel, blinding of outcome assessment, incomplete outcome data 
and selective reporting) was evaluated as low, high or unclear ROB.23
For the health economics analysis, two reviewers extracted the 
main characteristics of included studies (eg type of economic eval-
uation, perspective, time horizon, discount, sources of information 
and model type), relevant outcomes and costs (eg ICERs, sensitivity 
analyses results), sources of funding and conflict of interest. Two 
reviewers assessed the methodological limitations of the complete 
economic evaluations with the consensus on health economics cri-
teria checklist (CHEC).24 Transferability to the European context 
was assessed using the European Network of Health Economic 
Evaluation Databases (EURONHEED) checklist.25,26
2.6 | Data synthesis and analysis
Main results are described narratively and tabulated as summary of 
findings. For dichotomous data, results are pooled as incidence rate ra-
tios (IRR) and risks ratios (RR). For continuous data, results are reported 
as mean differences (MD), with 95% confidence intervals (CI). For each 
outcome, the change from baseline to the end of the treatment vs pla-
cebo was assessed. A random-effects model was used to pool data 
(Review Manager v 5.3). Where multiple arms were compared to a com-
mon placebo arm, standard errors were adjusted to avoid unit of analy-
sis error.27 Statistical heterogeneity between studies was assessed with 
the Cochrane chi-square test, and the magnitude of heterogeneity with 
the I2 statistic. To account for clinical heterogeneity, whenever possible 
subgroup analyses were performed for different doses, age groups, total 
IgE serum levels and biomarkers (FeNO, DPP4 and periostin). A post 
hoc subgroup analysis for the rate of severe asthma exacerbation fol-
lowing the reduction in the OCS dose was added. The median estimate 
reported in the control arms of the included RCTs was used as baseline 
risk to estimate absolute effects for each comparison.
For the economic evidence, results are summarized narratively 
and tabulated, including the ICERs and the degree of uncertainty.
2.7 | Certainty of evidence
The certainty (quality) of the evidence of efficacy, safety and eco-
nomic impact was rated as high, moderate, low or very low, for 
each outcome in line with the standard GRADE domains (ROB, im-
precision, inconsistency, indirectness and publication bias).28,29 To 
evaluate the imprecision, for each outcome the minimal important 
difference (MID) thresholds were considered where available.30-33 
For FEV1 the GDG panel recommended a MID of 0.20 litres (L).
3  | RESULTS
3.1 | Search process
The selection process is summarized in the PRISMA flow chart 
(Figure 1). From 3441 unique citations, from database searches we se-
lected 91 to be appraised as full text. Thirty-seven publications from 
28 RCTs were included: three RCTs (from three publications) for ben-
ralizumab,34-36 one RCT (from two publications) for dupilumab,37,38 
21 RCTs (from 27 publications) for omalizumab for the popula-
tion ≥ 12 years old39-64 and 3 RCTs (from five publications) for omali-
zumab for 6-20 years old65-69 (Table S2). Publications excluded due to 
population or outcomes of interest not relevant, different compari-
sons, or regulatory unapproved dose or route are included in Table S3.
3.2 | Characteristic of included studies
The description of studies included for the evidence of efficacy and 
safety are detailed in Table S1. All were randomized control trials, con-
ducted between 2011 and 2018, including patients with uncontrolled 
severe allergic asthma receiving the biological in addition to standard 
of care vs placebo. The follow-up under study medication ranged from 
12 to 56 weeks. The age of the patients included ranged from 12 to 
75 years old, except for omalizumab that included children 6-11 years 
old as well. Benralizumab trials evaluated 3208 patients (1602 on 
treatment vs 1606 on placebo), dupilumab trials, 1083 patients (721 
on treatment arm vs 362 on placebo), and omalizumab, 6847 patients 
(3754 on treatment vs 3,093 on placebo). The characteristics of stud-
ies included for the economical impact are presented in Table S4.
     |  1047AGACHE Et Al.
3.3 | Evidence of efficacy
The summary of the results and certainty of evidence per outcome 
are summarized in Tables 1,2,3, Table S8, Figures S1 and S2.
3.3.1 | Severe asthma exacerbation rate
Two RCTs for benralizumab,34 one RCT for dupilumab38 and six RCTs 
for omalizumab,42,44,51,54,55,68 reported annualized exacerbations 
rates. All three biologicals reduced asthma exacerbation rate com-
pared to standard of care with high certainty of the evidence: ben-
ralizumab IRR 0.63; 95%CI 0.50 to 0.81; dupilumab IRR 0.58; 95%CI 
0.47 to 0.73; and omalizumab IRR 0.56; 95%CI 0.45 to 0.69. No dif-
ferences were found for omalizumab between children 6-11 years 
old and adolescent/adults (P = .88).
3.3.2 | Asthma control
Two RCTs for benralizumab,34 one RCT for dupilumab38 
and three RCTs for omalizumab44,56,59 reported ACQ-6 
scores. Benralizumab (MD −0.17; 95%CI −0.34 to 0.00) and 
dupilumab (MD −0.27; 95%CI −0.40 to −0.14) improve asthma 
control compare to standard of care (high certainty of evidence). 
Omalizumab probably improves asthma control compared to 
standard of care in adolescent/adults (MD −0.38; 95%CI −0.68 
to −0.09; moderate certainty). ACQ was not evaluated for chil-
dren 6-11 years old. None of the biologicals showed a reduction 
above the MID.
3.3.3 | Global evaluation of treatment effectiveness
Global evaluation of treatment effectiveness (GETE) was evaluated for 
omalizumab vs standard of care. Ten RCTs reported GETE assessed by 
physicians/investigators40,43,47,48,54,59,62,63,66,68 and eight RCTs GETE 
assessed by patients.40,44,47,54,59,62,63,68 The overall effect for GETE 
evaluated by physicians/investigators showed an increase with high 
certainty of evidence in the proportion of treatment effectiveness 
evaluations rated as excellent or good (RR 1.50; 95%CI 1.32 to 1.70). 
There were no differences between children 6-11 years old (RR 1.41; 
95%CI 1.25 to 1.58) and adolescent/adults (RR 1.55; 95%CI 1.31 
to 1.83) (P = .34). The overall effect for GETE evaluated by patients 
showed a similar significant improvement (RR 1.49; 95%CI 1.26 to 
1.77). A significantly larger increase in GETE was observed in adoles-
cent/adults (RR 1.57; 95%CI 1.3 to 1.89) compared to the 6-11 years 
old population (RR 1.11; 95%CI 1.01 to 1.23) (P = .001).
F I G U R E  1   Study flow chart for the 
evaluation of evidence of efficacy and 
safety
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3.3.4 | Quality of life (QoL)
Asthma quality of life questionnaire (AQLQ) score was reported 
for benralizumab in two RCTs34 and for omalizumab in nine 
RCTs.40,47,51,52,54,55,62,63,67 Benralizumab improved QoL> 0.5 points 
from baseline in the population who met atopy and IgE criteria (MD 0.1; 
95%CI −0.08 to 0.28; high certainty); however, the improvement was 
below the MID. Omalizumab increases with high certainty of evidence 
the QoL in adults and children: RR 1.32; 95%CI 1.16-1.51. There was no 
difference between adolescent/adults (RR 1.31; 95%CI 1.14-1.51) and 
children 6-11 years old (RR 1.43; 95%CI 1.12 to 1.83) (P = .37).
3.4 | Evidence for safety
3.4.1 | Drug-related adverse events
Drug-related AE were reported for benralizumab in one RCT35 
and in seven RCTs for omalizumab.41,43,50,54,60,63,66 Both biologi-
cals showed an increase in drug-related AE compared to standard 
of care: benralizumab RR 1.41 (95%CI 0.87 to 2.27; low certainty); 
omalizumab (children 6-11 years old and adolescents/adults) RR 1.27 
(95% CI 0.93 to 1.72; moderate certainty of evidence). No differ-
ences were observed between adolescent/adults (RR 1.2; 95%CI 
TA B L E  1   Summary of findings for benralizumab efficacy and safety compared to standard of care for allergic asthma
Outcomes
No of participants 
(studies) follow-up








Risk difference with 
Benralizumab*










13 per 1.000 5 fewer per 1.000 
(6 fewer to 2 
fewer)
Asthma control assessed with ACQ-6 






- The mean asthma 




Quality of Life assessed with quality 
of life questionnaire for 12 y and 
older [AQLQ(S)+12], between-group 





- The mean quality 
of Life was 0 
Mean change
MD + 0.1 (−0.08 to 
+0.28)
Any drug-related adverse event assessed 
with number of events—Urgent care 








105 per 1.000 43 more per 1.000 
(14 fewer to 133 
more)
Any drug-related serious adverse event









147 per 1.000 65 fewer per 1.000 
(114 fewer-65 
more)
Lung function assessed with 
prebronchodilator FEV1 (mL) 






- The mean lung 
function was 0 L
MD + 0.055 L 
(−0.025 to +0.136)
Note: GRADE Working Group grades of evidence High certainty: High confidence that the true effect lies close to that of the estimate of the effect.
Moderate certainty: Moderate confidence in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different.
Low certainty: Limited confidence in the effect estimate: the true effect may be substantially different from the estimate of the effect.
Very low certainty: Very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
Abbreviations: CI, confidence interval; MD, mean difference; and RR, risk ratio.
Explanations:
aIncluded studies were all funded by industry, and all showed positive results. No industry-independent observational or randomized studies were 
identified to contrast the results. Therefore, evidence was downgraded for potential publication bias.102
bFor ACQ-6, the minimal important difference is 0.5 points 30
cFor AQLQ(S) + 12, the minimal important difference is 0.5.32
dDowngraded one level due to indirectness (data from severe asthma patients that may have or may have not allergic asthma)
eThe effect may both be harmful or beneficial. Estimations are based on less than 300 events; thus, there is probably important imprecision.
fDowngraded because FEV1 is considered a surrogate outcome of asthma control of symptoms, with a variable correlation with asthma symptoms.103
gThe effect may both be harmful or beneficial. The minimal important difference (MID) for FEV1 is 0.20 L (Guidelines Development Group 
consensus).
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI). 
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0.92 to 1.57) and children 6-11 years old (RR of 6.78; 95% CI 0.90 
to 50.91) (P = .10).
3.4.2 | Drug-related serious adverse events
Drug-related SAE were reported for benralizumab in one RCT36 and 
for omalizumab in two RCTs.51,60 Benralizumab may reduce the inci-
dence of SAE (RR 0.56; 95%CI 0.22-1.44) but there is low certainty 
of evidence. Omalizumab may increase SAE in adolescent/adults 
(RR 1.62; 95%CI 0.76 to 3.45; 11 more per 1000 patients, from four 
fewer to 43 more) with low certainty of evidence. No drug-related 
SAE were reported for children 6-11 years old.
3.5 | Corticosteroid and rescue medication
3.5.1 | Inhaled corticosteroid dose
Inhaled corticosteroid dose dose reduction was evaluated only for 
omalizumab vs placebo in five RCTs.41,42,46,52,65 The addition of 
omalizumab reduced ICS dose both in children 6-11 years old and 
in adolescent/adults with high certainty of the evidence (overall ef-
fect MD −0.38; 95%CI −0.48 to −0.29). There were no differences 
between children 6-11 years old (MD −0.31; 95%CI −0.45 to −0.18) 
and adolescent/adults (MD −0.45; 95%CI −0.58 to −0.32) (P = .16).
3.5.2 | Oral corticosteroids dose
The reduction in OCS use from baseline was reported for omali-
zumab in a subpopulation of patients with severe asthma requiring 
OCS maintenance throughout the run-in phase (8 weeks prior to ran-
domization).45 Compared to standard of care, omalizumab showed a 
significant reduction in prednisolone equivalent milligrams per day 
at 32 weeks (MD −6.7; 95%CI −12.93 to −0.47).
3.5.3 | Rescue medication use (puffs/day)
The variation in rescue medication use was evaluated only for 
omalizumab, both in adolescent/adults 42,46,51,52,59 and in children 
TA B L E  2   Summary of findings of dupilumab compared to standard of care for allergic asthma
Outcomes
No of participants 
(studies) follow-up










Clinically significant exacerbations rate 











10 per 1.000 4 fewer per 1.000 
(5 fewer to 3 
fewer)
Asthma control assessed with asthma 






- The mean asthma 
control was 0
MD - 0.27 (−0.4 to 
−0.14)
Lung function assessed with forced 
expiratory volume in 1 second (FEV1 









MD + 0.15 L (+0.09 
to +0.2)
Note: GRADE Working Group grades of evidence.
High certainty: High confidence that the true effect lies close to that of the estimate of the effect.
Moderate certainty: Moderately confidence in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different.
Low certainty: Limited confidence in the effect estimate: the true effect may be substantially different from the estimate of the effect.
Very low certainty: Very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect 
Explanations.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI). 
Abbreviations: CI, confidence interval; MD, mean difference.
Explanations:
aThe study included was funded by Sanofi and Regeneron Pharmaceuticals. No industry-independent observational or randomized trials were 
identified to compare the results. The GDG members considered that there were no major concerns about potential publication/sponsorship bias
bThe effect of dupilumab is below the MID (0.5 points). 32
cDowngraded because FEV1 is considered a surrogate outcome of asthma control of symptoms, with a uncertain correlation with asthma 
symptoms.103
dThe minimal important difference (MID) for FEV1 is 0.20 L (GDG consensus).
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TA B L E  3   Summary of findings of omalizumab efficacy and safety compared to standard of care for allergic asthma
Outcomes
No of participants 
(studies) follow-up 
range










Annual rate of clinically significant 













14 per 1.000 616 fewer per 
1.000 (770 fewer 
to 378 fewer)






- The mean asthma 
control was 0 
point
MD 0.38 point 
lower (0.68 lower 
to 0.09 lower)h,i
Global evaluation of treatment 











418 per 1.000 209 more per 1.000 
(134 more to 292 
more)k
Clinically significant improvement 
of asthma quality of Life (≥0.5 from 
baseline) assessed with AQLQ 
Questionnaire (S)









563 per 1.000 180 more per 1.000 
(90 more to 287 
more)m








127 per 1.000 34 more per 1.000 
(9 fewer to 94 
more)







18 per 1.000 11 more per 1.000 
(4 fewer to 43 
more)
Lung function (FEV1) assessed with 
absolute FEV1 (L) change vs baseline
1209 (6 
RCTs)42,43,55,60-62
range 12-52 wk n,o
⨁⨁◯◯
LOW21-23b,p,q,r
- The mean lung 
function was 0 L
MD 0.17 L higher 
(0.02 higher to 
0.32 higher)s
Lung function (PEF) assessed with 








- The mean lung 
function was 0
MD 10.04 higher 
(7.49 higher to 
12.6 higher)
Decrease in inhaled corticosteroid 







- - SMD 0.38 SD lower 
(0.48 lower to 0.29 
lower)
Rescue medication use (puffs/day) 
assessed with change from baseline
3367 (7 
RCTs)41,42,52,54,59,66,68
16-52 wk 22, w
⨁⨁⨁⨁
HIGHb,d,x






MD 0.47 puff/day 
fewer (0.68 fewer 
to 0.27 fewer)
FeNO level change from baseline29, y 495 (3 RCTs)41,51,65 ⨁⨁⨁◯
MODERATE32,33,b,d,z




MD 4.65 ppb lower 
(7.39 lower to 1.92 
lower)aa
Note: GRADE Working Group grades of evidenceHigh certainty: High confidence that the true effect lies close to that of the estimate of the effect
Moderate certainty: Moderate confidence in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different
Low certainty: Limited confidence in the effect estimate: the true effect may be substantially different from the estimate of the effect
Very low certainty: Very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
Abbreviations: CI, confidence interval; MD, mean difference; RR, risk ratio; and SMD, standardized mean difference
Explanations: 
aClinical significant asthma exacerbation: episodes of asthma worsening requiring treatment with systemic corticosteroids.
bDespite some studies being at high risk of bias for some of the domains, the effect observed in all of them is similar.
cLanier included patients aged 6-12 y old, all had allergic asthma.68
dIncluded studies were all funded by industry, and all showed positive results. No industry-independent observational or randomized studies were 
identified to compare the results. Therefore, evidence was downgraded for potential publication bias.102
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6-11 years old.66,68 Omalizumab reduced with high certainty the 
rescue medication use in the overall population (MD −0.47; 95%CI 
−0.68 to −0.27). There were no differences between children 
6-11 years old (MD −0.41; 95%CI −0.66 to −0.15]) and adolescent/
adults (MD −0.52; 95%CI −0.80 to −0.24) (P = .55).
3.5.4 | Lung function
Forced exhalation volume in 1 second variation in litres was re-
ported in two RCT for benralizumab,34 one for dupilumab38 and 
six RCTs for omalizumab.42,43,55,60-62 Both dupilumab (MD 0.15; 
95%CI 0.09-0.20) and omalizumab (MD 0.17; 95%CI 0.02-0.32) 
improve FEV1 with low certainty of evidence. Benralizumab prob-
ably does not increase FEV1 in the population that met atopy and 
IgE criteria (MD 0.055; 95%CI −0.025-0.136; moderate certainty 
of evidence). None of the biologicals showed an increase in FEV1 
above the MID.
3.6 | Evidence of cost-effectiveness
After screening 1884 hits and reviewing 36 full text articles, 22 
economic evaluations were included (Figure 2, Table S3). Two stud-
ies evaluated benralizumab,70,71 one dupilumab 70 and twenty stud-
ies omalizumab72-91 (Table S3). Most of the studies excluded did not 
evaluate patients with allergic asthma (3/14), did not report health 
outcomes (3/14) or were conference abstracts (3/14) (Table S4).
For benralizumab, there was an important variation of ICER 
from 39 135 £ (low certainty of the evidence) to 412 000 $/QALY 
(moderate certainty of the evidence). The key driver for this differ-
ence is unclear since there is missing information in the report.71 
However, in both studies the ICER/ QALY was higher than the 
30 000 € threshold for the willingness to pay (Tables S5 and S6). 
Overall, the resources needed for adding the biologic treatment to 
standard therapy are mainly the cost of the drug and its administra-
tion (Table S7). The potential savings are related to decreased rate 
of hospitalization, emergency department care, primary care visits 
eNine studies included reported exacerbations as "patients who had ≥1 exacerbation," the pooled risk ratio was 0.59(95% CI 0.52-0.67). Three studies 
included reported clinically significant severe asthma exacerbation, the pooled rate ration was 0.51 (95% CI 0.39-0.67).
fThe pooled effect of risk ratio evaluated at 24-28 wk44,54,63,68 and at 48-52 wk.42,51,55,68 Lanier 2009 included patients aged 6-12 y old.
gDowngraded because the effect of omalizumab is beneficial but the upper side of the CI is less than the minimal important difference (MID = 0.5).32
hAsthma control using asthma control test (ACT) was assessed by three studies,43,56,65 the pooled mean different was 0.57(95% CI 0.17-0.97). We 
also included the ACQ scores assessed by five studies,46,51,52,59,68 the pooled standard mean difference was −0.20 (95% CI −0.26 to −0.14)
iThe pooled effect of ACQ-6 evaluated at 16 wk,44 24-32 wk44,59 and at 52 wk.56
jAlthough there were a high I2 (67%.), this was influenced by only one study with low number of events.
kThe pooled data were assessed at 16 and 20 wk,48,62 and 52 wk68; Other studies evaluated at 24-28 wk. GETE evaluated by patients show that 
omalizumab is more effective than placebo, the risk ratio was 1.49 (1.26-1.77), see full text report.
lStatistically significant (I2 = 83%), but probably unimportant heterogeneity.
mThe mean change of AQLQ scores was assessed by seven studies, the pooled standard mean difference was 0,34 (95% IC 0.18-0.49)
nMilgrom reported FEV1 in children (6-12 y old) for 28 wk follow-up.64 The mean change from baseline was 93.9 mL in the omalizumab group and 
28.3 mL in the placebo group. Lanier reported between-group differences in FEV1 at week 48 and 52 in 40 mL (P = .28) and 52 mL (P = .16).41
oLung function was also reported as ratio FEV1/FVCx100. Busse reported the ratio in 77.5 ± 0.38 in the intervention group and 77.3 ± 0.36 in the 
placebo group.63 Milgrom also reported mean FVC in children (6-12 y old) for 28 wk follow-up. Mean FVC change from baseline was 132.7 in the 
omalizumab group and 132.7 mL in the placebo group at week 28.64 See full text report.
pDowngraded because FEV1 and PEF are considered surrogate outcomes for asthma control, with an inconsistent correlation with asthma 
symptoms.101
qThe minimal important difference (MID) for FEV1 is 0.20 L (Guidelines Development Group consensus).
rIncluded studies were all funded by industry, and all showed positive results. One observational study showed similar results 102; therefore, we did 
not downgrade for potential publication bias.
sThe predicted value for prebronchodilator FEV1 was assessed by 6 studies, the pooled standard mean difference was 1.05 (95% CI 0.35-1.75), see 
full text report.
tMilgrom 2001 reported PEFR in children (6-12 y old) with 28 wk of follow-up. Mean morning PEFR change from baseline was 8.5 L/min in the 
omalizumab group, and 1 L/min in the placebo group at week 28)
uAverage MID is 18.8 L/min 30
vHigh heterogeneity (91%); Not downgraded as all effects favour intervention.
wFor rescue medication use MID is the reduction by 0.81 puffs/day 30
xStatistically significant (68% [P = .004]) but probably unimportant heterogeneity.
yThe MID of FeNO change from baseline is more than 10 ppb.33
zDowngraded because FeNO is not consistently considered a good surrogate of asthmatic inflammation.105,106
aaFeNO change was reported according to IgE level by one study YY.64 The median percentage change was −7.2 (for IgE 30-300 IU/mL) and −16 (for 
IgE 700-2,000 IU/mL) in the omalizumab group and 64 in the placebo group.
abThe effect may both be harmful or beneficial.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI). 
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and the management of a clinically significant severe exacerbation 
(Tables S5 and S6).
For dupilumab, the reported ICER was 269 000 $ for the “re-
sponder to treatment” scenario. The uncertainty resides in the po-
tential ROB in the utility estimates for the biological and standard 
therapy for the nonexacerbation health state, for standard therapy 
and annual exacerbation, and costs of chronic OCS use (moderate 
certainty of the evidence) (Table S6 and S7).
For omalizumab, there is important variation across studies in 
terms of the cost-effectiveness results. Cost-utility Markov model 
studies with low ROB (high quality studies) consistently show ICER/ 
QALY values higher than the willingness to pay threshold in most 
European countries with moderate certainty of the evidence. Low 
quality studies reported ICER values lower than 30 000 €, with very 
low certainty of the evidence. The difference can be explained by 
the fact that the low quality studies assumed a higher asthma-re-
lated mortality risk and a higher QoL improvement with omalizumab. 
Furthermore, these studies were limited in their time horizon to up 
to 1 year (Table S6 and S7).
4  | DISCUSSION
4.1 | Main findings
Overall, the included studies were of low concern of ROB for most 
of the reported asthma-related outcomes. All included studies were 
funded by the industry and all showed positive results, which raised 
concerns of potential sponsorship bias. The main reasons to down-
grade the certainty of evidence were ROB due to the use of not 
validated tools for some outcomes, imprecision (ie ACQ, AQLQ) and 
indirectness (ie FEV1, FeNO as surrogate outcomes).
The current systematic review of efficacy showed with high cer-
tainty that benralizumab, dupilumab and omalizumab as add-on to 
standard of care reduce the exacerbation rates for patients with al-
lergic asthma older than 12 years (adolescent/adults). Similarly, for 
children 6-11 years old with allergic asthma, omalizumab as add-on 
treatment significantly reduces the exacerbations rates.
The improvement in asthma control with benralizumab and 
dupilumab did not reach the MID. Omalizumab improves asthma 
control if GETE is considered; however, the results are inconsis-
tent with the ACQ score analysis. There is no evidence to support 
a MID for GETE. However, the first three response levels of both 
the physician and patient versions of the GETE (“complete control 
of asthma,” “marked improvement of asthma,” and “discernible, but 
limited improvement of asthma”) are clearly differentiated from 
each other and this clear differentiation is associated with clini-
cally important differences in terms of clinical indices and some 
AQLQ subscales.92
Omalizumab also improves quality of life for children and ad-
olescents/adults. Benralizumab did not show a clinically relevant 
improvement.
Rescue medication use (puffs/day), inhaled and oral corticoste-
roid use were evaluated only for omalizumab. The current SR showed 
with high certainty a reduction, both for children and adolescent/
adults.
Although short-term safety data are reassuring, there is low to 
very low certainty for serious adverse effects. The very low cer-
tainty derives from the fact that drug-related AEs were reported 
combined with worsening of asthma symptoms or were not reported 
in detail in the main publication or in the supplementary documents.
All three biologicals evaluated had with moderate certainty 
of the evidence an ICER/QALY value above the willingness to pay 
threshold of 30 000 €.
4.2 | Current results in the context of 
previous results
Similar to results reported by this SR, all previous systematic reviews 
evaluating benralizumab, dupilumab and omalizumab efficacy and 
safety in adolescent/adults with allergic severe asthma reported a 
reduction of approximately half of annualized exacerbations in the 
population.93-97 The reduction in the exacerbation rates reported 
by the previous systematic reviews that evaluated omalizumab in 
children 6-11 years old was also very similar.96-98 Aligned with the 
current results the systematic review that evaluated asthma control 
and quality of life96 in adolescent/adults population for omalizumab 
reported an improvement on these outcomes. The current SR high-
lighted with high certainty that the improvement in QoL following 
the addition of omalizumab is clinically relevant.
An important difference between the current SR and the pre-
vious SRs is the assessment of the certainty of evidence using the 
GRADE approach. With the exception of Normansell, all previous 
SRs limited their evaluation to the risk of bias of the included trials. 
The current SR evaluated the heterogeneity, imprecision and the in-
directness of the evidence. As an example, MID used for the assess-
ment of imprecision, enabled us to determine the clinical relevance 
of the variation for each outcome.
A previous SR of 20 economic evaluations included 19 studies 
that assessed the cost-effectiveness of omalizumab. Ten studies 
concluded that omalizumab was cost-effective for base-case sce-
narios, four studies showed that omalizumab was not cost-effective, 
and the remaining studies reported that omalizumab was cost-ef-
fective only when targeted to specific severe subgroups or when 
given considerable price discounts. The key drivers of cost-effec-
tiveness included day-to-day health-related QoL, asthma-related 
mortality, acquisition price of biological therapy and time horizon. 
The SR concluded that in order to improve the value for biologicals 
in asthma they should target specific populations (ie responders) or 
discounted acquisition price should be granted.99 Another review 
of 72 studies assessing the cost-effectiveness of asthma treatment 
reported that among patients with uncontrolled severe persistent 
allergic asthma, omalizumab could be cost-effective in patients 
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with more severe disease. The quality among studies was uneven 
and the main cost-effectiveness drivers were the cost or rate of 
asthma exacerbations, the cost or rate of use of asthma medication, 
asthma mortality risk and the rate of utilization of health services 
for asthma.100 A third review of 53 economic evaluations, evaluat-
ing patients with asthma and COPD, included nine assessments of 
omalizumab use. This review concluded that few economic evalu-
ations used validated models and identified controversies among 
results.101
4.3 | Strengths and limitations
The current SR has several strengths. A comprehensive evaluation of 
both desirable and undesirable effects of the use of benralizumab, 
dupilumab and omalizumab for allergic asthma was conducted, in-
cluding the assessment of their economic impact. This compilation 
of outcomes provided an improved perspective of the biologicals 
profile. Rigorous methods including the GRADE approach to rate 
the certainty of the evidence were used, leading to transparent and 
precise judgement of the quality of evidence. The most updated 
results available from the included RCTs were included and only 
licensed doses and/or routes of the biologicals were considered. 
Results are provided in friendly tabulated summaries using optimal 
presentation format for patients, clinicians and policymakers, thus 
offering a consistent support for the decision of use biologicals for 
patients with uncontrolled severe allergic asthma.
There are however several limitations. The basal exacerbation 
rate was used to estimate the absolute benefit for each drug/anal-
ysis. However, we did not perform a subgroup or sensitivity analy-
sis based on the basal exacerbation rate. To ensure the robustness 
of the results, based on high quality data observational studies that 
could have been informative for some of the outcomes with low or 
very low quality evidence from RCTs (eg serious adverse events) 
were not included in the SR. Only English language articles were in-
cluded; however, the risk of selection bias is probably small because 
previous systematic reviews were carefully screened, and the GDG 
included several international experts in the field, thus the possibility 
of missing results from non-English articles is unlikely. A “the novo” 
economic analysis for the cost-effectiveness outcomes was not 
F I G U R E  2   Study flow chart for the 
economic evidence
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conducted. Instead, a global perspective on the use of biologicals in 
different health systems, with a rigorous and explicit critical appraisal 
of the available evidence, was chosen. This approach could be useful 
for the decisions of using biologicals across different countries.
4.4 | Implications for practice and research
Despite biologicals showing an improvement in asthma-related 
critical and important outcomes, the observed overall effect is rela-
tively modest (reducing exacerbations but only probably improving 
asthma control, quality of life or lung function). Given the high cost 
of these drugs their use will probably be limited to very specific 
circumstances (eg patients with severe asthma uncontrolled under 
standard treatment). In this context, panels are likely to formulate 
conditional recommendations on the use of biologicals.
Although short-term safety data are reassuring, more accurate re-
porting is warranted, in combination with long-term safety evaluation, 
including observational studies and registries.104 For omalizumab, 
there are good data available to support its efficacy and safety in the 
paediatric population;104 however, for benralizumab and dupilumab 
the data are limited highlighting the urgent unmet need for rigorous 
trials with biologicals in severe asthma in the paediatric population.
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